MetLife Investment Management LLC Boosts Holdings in Repligen Co. (NASDAQ:RGEN)

MetLife Investment Management LLC increased its position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 8.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 29,774 shares of the biotechnology company's stock after purchasing an additional 2,428 shares during the period. MetLife Investment Management LLC owned 0.05% of Repligen worth $4,286,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the company. UMB Bank n.a. lifted its holdings in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company's stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new position in shares of Repligen in the 4th quarter valued at about $216,000. Van ECK Associates Corp grew its position in shares of Repligen by 7.8% during the fourth quarter. Van ECK Associates Corp now owns 42,226 shares of the biotechnology company's stock worth $6,078,000 after buying an additional 3,066 shares in the last quarter. Stephens Investment Management Group LLC increased its stake in shares of Repligen by 7.4% during the fourth quarter. Stephens Investment Management Group LLC now owns 536,801 shares of the biotechnology company's stock worth $77,267,000 after buying an additional 37,057 shares during the period. Finally, Sanctuary Advisors LLC acquired a new stake in Repligen in the third quarter valued at approximately $233,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Price Performance

RGEN stock traded down $3.32 during midday trading on Wednesday, hitting $136.11. 163,348 shares of the stock were exchanged, compared to its average volume of 737,722. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44. The stock has a market cap of $7.64 billion, a price-to-earnings ratio of -266.88, a PEG ratio of 4.54 and a beta of 1.27. Repligen Co. has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The stock's 50-day moving average price is $139.19 and its 200-day moving average price is $145.93.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The company had revenue of $169.17 million during the quarter, compared to analysts' expectations of $163.65 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The firm's quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.28 earnings per share. Research analysts predict that Repligen Co. will post 1.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on RGEN shares. JPMorgan Chase & Co. dropped their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating on the stock in a report on Tuesday. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Monday. HC Wainwright reiterated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Evercore ISI began coverage on Repligen in a research note on Tuesday, March 18th. They set an "in-line" rating and a $155.00 price target for the company. Finally, Canaccord Genuity Group lowered their price objective on shares of Repligen from $170.00 to $150.00 and set a "hold" rating on the stock in a research report on Wednesday, April 16th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $174.58.

Insider Transactions at Repligen

In other news, Director Margaret Pax purchased 250 shares of the stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the acquisition, the director now directly owns 1,043 shares in the company, valued at $157,169.67. This represents a 31.53 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.